Awaiting development: Guidance and quality standards

Showing 131 to 140 of 285

Guidance and quality standards awaiting development
Title	Type
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment [ID3869]	Technology appraisal guidance
Lurbinectedin with atezolizumab for maintenance treatment of extensive-stage small-cell lung cancer TS ID 11970	Technology appraisal guidance
Luspatercept for treating anaemia in non-transfusion dependent beta-thalassaemia [ID3870]	Technology appraisal guidance
Lutetium oxodotreotide with octreotide for newly diagnosed unresectable or metastatic gastroenteropancreatic neuroendocrine tumours [ID6315]	Technology appraisal guidance
LY3209590 for treating type 1 diabetes in people on multiple daily insulin injections [ID6498]	Technology appraisal guidance
LY3209590 for treating type 2 diabetes in people on daily insulin injections [ID6499]	Technology appraisal guidance
Masitinib with riluzole for treating amyotrophic lateral sclerosis TS ID 10728	Technology appraisal guidance
Mavorixafor for treating WHIM syndrome ID3946	Technology appraisal guidance
Mepolizumab for reducing eosinophilic exacerbations of chronic obstructive pulmonary disease [ID1237]	Technology appraisal guidance
Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment TS ID 12121	Technology appraisal guidance